Another group reported the development of ICI-CeD in a patient who received pembrolizumab for locally recurrent melanoma.17 The patient developed symptoms within a week of the first infusion of pembrolizumab, and ICI-CeD was confirmed by histology and serum tTG-IgA. This evidence concerns the gene CD79A and melanoma.